Biogen (BIIB) Remains Buy at Deutsche Bank Ahead of Nov. Tecfidera EU Decision

October 28, 2013 11:45 AM

Deutsche Bank today maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $270.00. Comments follow Q3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found